A Safety and Pharmacokinetic Study of ER OROS Paliperidone in Pediatric Patients With Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder

NCT00796081 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia
Schizoaffective Disorder
Schizophreniform Disorders

Interventions

DRUG: ER OROS paliperidone, paliperidone ER

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.